These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33129291)

  • 1. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.
    Mohebi F; Tavakolpour S; Teimourpour A; Toosi R; Mahmoudi H; Balighi K; Ghandi N; Ghiasi M; Nourmohammadpour P; Lajevardi V; Abedini R; Azizpour A; Nasimi M; Daneshpazhooh M
    BMC Dermatol; 2020 Oct; 20(1):13. PubMed ID: 33129291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
    Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
    Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score.
    Rahbar Z; Daneshpazhooh M; Mirshams-Shahshahani M; Esmaili N; Heidari K; Aghazadeh N; Hejazi P; Ghajarzadeh M; Chams-Davatchi C
    JAMA Dermatol; 2014 Mar; 150(3):266-72. PubMed ID: 24429657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in Pemphigus Patients Measured by Area Index and Intensity Score.
    Patsatsi A; Kyriakou A; Giannakou A; Pavlitou-Tsiontsi A; Lambropoulos A; Sotiriadis D
    Acta Derm Venereol; 2014 Mar; 94(2):203-6. PubMed ID: 23995461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.
    Hébert V; Boulard C; Houivet E; Duvert Lehembre S; Borradori L; Della Torre R; Feliciani C; Fania L; Zambruno G; Camaioni DB; Didona B; Marinovic B; Schmidt E; Schumacher N; Hünefeld C; Schanz S; Kern JS; Hofmann S; Bouyeure AC; Picard-Dahan C; Prost-Squarcioni C; Caux F; Alexandre M; Ingen-Housz-Oro S; Bagot M; Tancrede-Bohin E; Bouaziz JD; Franck N; Vabres P; Labeille B; Richard MA; Delaporte E; Dupuy A; D'Incan M; Quereux G; Skowro F; Paul C; Livideanu CB; Beylot-Barry M; Doutre MS; Avenel-Audran M; Bedane C; Bernard P; Machet L; Maillard H; Jullien D; Debarbieux S; Sassolas B; Misery L; Abasq C; Dereure O; Lagoutte P; Ferranti V; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P; ;
    J Invest Dermatol; 2019 Jan; 139(1):31-37. PubMed ID: 30301637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
    Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
    Front Immunol; 2019; 10():2571. PubMed ID: 31781098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability and convergent validity of two outcome instruments for pemphigus.
    Rosenbach M; Murrell DF; Bystryn JC; Dulay S; Dick S; Fakharzadeh S; Hall R; Korman NJ; Lin J; Okawa J; Pandya AG; Payne AS; Rose M; Rubenstein D; Woodley D; Vittorio C; Werth BB; Williams EA; Taylor L; Troxel AB; Werth VP
    J Invest Dermatol; 2009 Oct; 129(10):2404-10. PubMed ID: 19357707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Oral Disease Severity Score validated for use in oral pemphigus vulgaris.
    Ormond M; McParland H; Donaldson ANA; Andiappan M; Cook RJ; Escudier M; Hullah E; Higham J; McMillan R; Taylor J; Shirlaw PJ; Challacombe SJ; Setterfield JF
    Br J Dermatol; 2018 Oct; 179(4):872-881. PubMed ID: 29297927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
    Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ODSS vs. ABSIS and PDAI oral parts in pemphigus vulgaris: inter-rater reliability and testing times.
    Shamabadi A; Yazdinezhad S; Sadeghi Y; Moradi AR; Yazdchi A; Teymourpour A; Faramarzi A; Seirafi R; Balighi K; Mahmoudi H; Daneshpazhooh M
    Oral Dis; 2023 Oct; 29(7):2696-2704. PubMed ID: 35852132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between salivary and serum anti-desmoglein 1 and 3 antibody titres using ELISA and between anti-desmoglein levels and disease severity in pemphigus vulgaris.
    De D; Khullar G; Handa S; Joshi N; Saikia B; Minz RW
    Clin Exp Dermatol; 2017 Aug; 42(6):648-650. PubMed ID: 28543318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity score indexes for blistering diseases.
    Daniel BS; Hertl M; Werth VP; Eming R; Murrell DF
    Clin Dermatol; 2012; 30(1):108-13. PubMed ID: 22137234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary and Serum Anti-Desmoglein 1 and 3 ELISA and Indirect Immunofluorescence in Pemphigus Vulgaris: Correlations with Serum ELISA, Indirect Immunofluorescence and Disease Severity.
    Koopai M; Mortazavi H; Khatami A; Khodashenas Z
    Acta Dermatovenerol Croat; 2018 Jun; 26(2):91-99. PubMed ID: 29989863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid.
    Fujio Y; Kojima K; Hashiguchi M; Wakui M; Murata M; Amagai M; Yamagami J
    J Dermatol Sci; 2017 Mar; 85(3):208-215. PubMed ID: 28012821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Tracking of Autoantibody Levels in a Pemphigus Vulgaris Patient: Support for a Role of Anti-Desmoglein 1 Autoantibodies as Predictors of Disease Progression.
    Abidi NY; Lainiotis I; Malikowski G; Seiffert-Sinha K; Sinha AA
    J Drugs Dermatol; 2017 Feb; 16(2):135-139. PubMed ID: 28300855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The elevated level of osteopontin in patients with pemphigus vulgaris: A cytokine-like protein with a therapeutic potential.
    Ketabi Y; Nasiri S; Kheirodin M; Tavakolpour S; Mozafari N
    Dermatol Ther; 2019 Jul; 32(4):e12973. PubMed ID: 31136685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of conventional and conformational anti-desmoglein antibodies with phenotypes and disease activities in patients with pemphigus vulgaris.
    Li Z; Zhang J; Xu H; Jin P; Feng S; Wang B
    Acta Derm Venereol; 2015 Apr; 95(4):462-5. PubMed ID: 25178305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of anti-desmoglein antibodies levels and other laboratory indexes as objective comprehensive indicators of patients with pemphigus vulgaris of different severity: a single-center retrospective study.
    Lin X; Li X
    Clin Exp Med; 2023 Jun; 23(2):511-518. PubMed ID: 35445951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ear, Nose, and Throat Involvement in Pemphigus Vulgaris in Comparison with Pemphigus Severity Scoring Systems: A Cross-sectional Study.
    Bilgic-Teme A; Cem Temel I; Bostancı-Toptas A; Turhan M; Bozkurt S; Uzun S
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):283-288. PubMed ID: 30665476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.